Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
During clozapine initiation, titration speed and concomitant valproate administration have been reported as risk factors for clozapine-induced fever and myocarditis. We tested the risk of concomitant valproate administration by stratifying patients according to titration rate. Concomitant valproate use was only associated with increased inflammatory adverse events in the slower titration group. The frequency of inflammatory adverse events was approximately 30 % during faster titration, regardless of concomitant valproate administration. However, the faster titration group with valproate had a higher frequency of severe adverse effects such as myocarditis. Clinicians should avoid concomitant valproate administration during clozapine initiation, regardless of titration rate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:334 |
|---|---|
| Enthalten in: |
Psychiatry research - 334(2024) vom: 19. März, Seite 115810 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kikuchi, Yuki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
614OI1Z5WI |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 19.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.psychres.2024.115810 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368721981 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368721981 | ||
| 003 | DE-627 | ||
| 005 | 20240319232738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.psychres.2024.115810 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM368721981 | ||
| 035 | |a (NLM)38382186 | ||
| 035 | |a (PII)S0165-1781(24)00095-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kikuchi, Yuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a During clozapine initiation, titration speed and concomitant valproate administration have been reported as risk factors for clozapine-induced fever and myocarditis. We tested the risk of concomitant valproate administration by stratifying patients according to titration rate. Concomitant valproate use was only associated with increased inflammatory adverse events in the slower titration group. The frequency of inflammatory adverse events was approximately 30 % during faster titration, regardless of concomitant valproate administration. However, the faster titration group with valproate had a higher frequency of severe adverse effects such as myocarditis. Clinicians should avoid concomitant valproate administration during clozapine initiation, regardless of titration rate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fever | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Pneumonia | |
| 650 | 7 | |a Clozapine |2 NLM | |
| 650 | 7 | |a J60AR2IKIC |2 NLM | |
| 650 | 7 | |a Valproic Acid |2 NLM | |
| 650 | 7 | |a 614OI1Z5WI |2 NLM | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 700 | 1 | |a Komatsu, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Otsuka, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Fumiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Yada, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Tanifuji, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Tomita, Hiroaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Psychiatry research |d 1982 |g 334(2024) vom: 19. März, Seite 115810 |w (DE-627)NLM000464988 |x 1872-7123 |7 nnns |
| 773 | 1 | 8 | |g volume:334 |g year:2024 |g day:19 |g month:03 |g pages:115810 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.psychres.2024.115810 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 334 |j 2024 |b 19 |c 03 |h 115810 | ||